GBPDC: Gut-Brain in PD Consortium Master Protocol

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21-80
SponsorDuke University

About this trial

The purpose of this research study is to identify the role that the gut-brain axis, the group of nerves that connect the brain and gut, plays in Parkinson's disease (PD). The National Institute of Diabetes and Digestive and Kidney Diseases is sponsoring this research study.

During this study, specific groups of participants, also known as "cohorts", will be identified based on the severity of their PD. There will also be a cohort enrolling participants who do not have Parkinson's and a cohort enrolling participants that are at risk for developing PD. Each of these cohorts will be compared to the others to assess the differences in the gut-brain connection.

Participants in this study will:

* meet with a medical provider * answer questionnaires * give samples of blood, stool, and saliva * have X-rays taken while swallowing different foods (swallowing study) * have X-rays taken to see how long it takes markers to move through their colon (colon transit study) * have a flexible sigmoidoscopy, where a doctor looks inside the lower part of the colon and takes small tissue samples (biopsies) from the mucosa (lining) * have samples taken of their skin * have an anorectal manometry and a balloon expulsion test, where a small tube and balloon are placed in the rectum to measure muscle function.

Participation in the study will last up to 24 months (2 years).

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Aged ≥21 years old and ≤80 years old

Clinical diagnosis of PD as defined by Movement Disorder Society (MDS) PD Criteria

Adequate visual, hearing, cognitive, and physical ability

Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures. Because longitudinal participation is important to the scientific goals of the program, a "best estimate" of interest, commitment, and geographic feasibility for three years will be documented by the enrolling investigator after interview with the potential enrollee

Disqualifiers

Diagnosis of secondary or atypical parkinsonism

Hemoglobin (Hgb) <10

Platelets <70,000

Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) > 2 1/2 times upper limit of normal (ULN)

Trial population

Patients at the NIDDK designated Gastroenterology Neurology Research Centers

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

250 Participants
are grouped into 3 trial groups
Group A: Household Controls
Group B: People with Parkinson's disease
Group C: Prodromal Parkinson's disease

Trial outcomes

Primary outcomes

1

GI influences on PD

Trait and State cross-sectional evaluation of GI influences on PD

Time frame
enrollment to end of observation at 24 months
2

Co-associations components of the GBA

Cross-sectional co-associations components of the GBA

Time frame
enrollment to end of observation at 24 months

Secondary outcomes

Other outcomes

1

GBA Disruption and Parkinson's disease Progression

GBA disruption triggered by microbiota dysbiosis (or another GI component of the GBA) predicts PD progression (both motor and non-motor dysfunction/symptoms including GI over time).

Time frame
enrollment to end of observation at 24 months
2

GBA Disruption and Prodromal Participants

Degree of the "type" or "nature" or "form" of the GBA disruption predict development of PD in prodromal participants over time.

Time frame
enrollment to end of observation at 24 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Duke University

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

University of Chicago

Collaborator

Rush University Medical Center

Collaborator

Massachusetts General Hospital

Collaborator

Stanford University

Collaborator

Medical University of South Carolina

Collaborator

Columbia University

Collaborator

Mayo Clinic

Collaborator